Clinical trials
Phase 2 Thrombosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
63 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 3 |
| 2003 | 1 |
| 2004 | 4 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 38 |
| Terminated | 10 |
| Unknown status | 8 |
| Recruiting | 4 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| ARCA Biopharma, Inc. | 4 |
| Bristol-Myers Squibb | 4 |
| Aronora, Inc. | 2 |
| Bayer | 2 |
| Daiichi Sankyo | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Mercator MedSystems, Inc. | 2 |
| Sanofi | 2 |
| Alexion Pharmaceuticals, Inc. | 1 |
| Arthur Pancioli | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Thrombosis | 63 |
| Hemorrhage | 9 |
| Stroke | 9 |
| Ischemic Stroke | 8 |
| Venous Thrombosis | 7 |
| Embolism and Thrombosis | 5 |
| Pulmonary Embolism | 5 |
| Inflammation | 4 |
| Venous Thromboembolism | 4 |
| Anemia, Hemolytic | 3 |
Trials
Showing 26 to 50 of 63. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.